The Structure of a CXCR4:Chemokine Complex by Tracy Marie Handel
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OPINION ARTICLE
published: 05 June 2015
doi: 10.3389/fimmu.2015.00282
The structure of a CXCR4:chemokine complex
Tracy Marie Handel*
University of California, San Diego, CA, USA
*Correspondence: thandel@ucsd.edu
Edited by:
Bernhard Moser, Cardiff University, UK
Reviewed by:
Krishna Rajarathnam, University of Texas Medical Branch, USA
Keywords: CXCR4, metastasis, chemokines, membrane protein structure, protein–protein complex
CXCR4 was the first chemokine receptor
to be identified as an HIV coreceptor in
1996 (1). Along with the importance of
CXCR4 in development, it was also dis-
covered as a key chemokine receptor in
the metastasis of breast (2) and numerous
other cancers (3). These were the main rea-
sons that motivated us to pursue structural
studies of CXCR4 with synthetic inhibitors
and chemokines. However, my laboratory
took a rather circuitous route to this goal,
and I did a lot of reinventing myself as a
scientist along the way.
As background, I got my Ph.D. in chem-
istry/membrane biophysics at the Califor-
nia Institute of Technology, and then in
1989 accepted a postdoctoral position to
do “protein design” with Bill DeGrado at
E. I. Du Pont de Nemours (we called it
Du Pont University back then, given the
amazing freedom we had to do truly basic
research). Du Pont (primarily a chemi-
cal company) formed a Joint Venture and
became Du Pont Merck Pharmaceuticals;
and when I was transitioning to a full time
employee in 1992, we were tasked with
coming up with new therapeutic targets
for the expanded pharmaceutical side of
the business. I was hired as part of the
macromolecular NMR group headed by
Peter Domaille, and thus my target choices
were biased by some of the exciting work
emerging from the structural biology com-
munity. This included the first structure
of a chemokine, interleukin-8 (IL-8, now
CXCL8), which was published in 1990 by
Angela Gronenborn’s NMR group at NIH
(4). I remember being intrigued by the
dimeric structure and thinking (as they
described in their paper) that the dimeric
architecture of two alpha helices on top
of a beta sheet platform might provide
a perfect binding site for the IL-8 recep-
tor, as it was reminiscent of the human
class I histocompatibility antigen HLA-
A2 binding pocket for antigenic peptides.
In 1989, two separate groups had cloned
the gene for the related CC chemokine,
monocyte chemotactic protein-1 (MCP-1,
also called MCAF, now CCL2) (5, 6), and
although the MCP-1 receptor (CCR2) had
not yet been cloned, it looked like this
system might be a good target for inflam-
mation. It was consequently adopted as
a focus of the Du Pont Merck inflam-
matory disease group, with the goal of
inhibiting the receptor. Inspired by the
IL-8 structure and the expectation that
MCP-1 would also be a tractable target
for NMR, Peter Domaille and I began
working on its structure around 1992. We
were hoping to obtain the structure of
the first CC chemokine, but not surpris-
ingly, the powerhouse NIH group beat
us by a long shot and solved MIP-1β in
1994 (7), as did Nick Skelton and Tom
Schall at Genentech, who solved the struc-
ture of RANTES in 1995 (8). Neverthe-
less, we persisted, and although I left Du
Pont Merck for a faculty position at the
University of California Berkeley in 1994,
we published the structure of MCP-1 in
1996 (9).
At Berkeley, I continued working on
MCP-1 in collaboration with a group at
Roche led by Kurt Jarnagin. A major ques-
tion that arose from the prevalence of
dimeric chemokine structures that had
been solved was whether they bound recep-
tors as dimers (the prevailing hypothe-
sis) or as monomers. By identifying a
mutant that was incapable of dimeriz-
ing but was as potent as WT MCP-1 in
migration and receptor binding assays, we
demonstrated that it bound CCR2 as a
monomer (10). This conclusion was con-
sistent with a prior study by Ian Clark-
Lewis who had shown that IL-8 was
also a functional monomer (11). We also
did a fairly comprehensive mutagenesis
study of the residues involved in bind-
ing and signaling and came up with
a model, which was published in 1999
(Figure 1A) (12). Although we never prop-
erly docked MCP-1 to the rhodopsin-based
model of the receptor, we were quali-
tatively on the right track of what the
structure might look like. However, it was
just a model based on mutagenesis data,
and I really wanted to determine high-
resolution structures of intact receptors
with chemokines and/or small molecule
antagonists.
Because membrane receptors are so
challenging, there was no way I was
going to even consider working on intact
chemokine receptor structures until/unless
I got tenure at Berkeley, and fortunately
that occurred in 2000. In 2002, I man-
aged to hire a talented postdoc, Samantha
Allen, from University of Bristol. She had
a background in protein folding studies of
bacteriorhodopsin, was interested in mov-
ing onto studies of eukaryotic membrane
receptors and had the bravery (or per-
haps naivety) to join me in the pursuit of
chemokine receptor structures. Not having
a track record in the expression, biochem-
istry or structural biology of membrane
receptors, it was very difficult to get fund-
ing. Fortunately, Richard Horuk managed
to convince his company, Berlex, to provide
matching funds for a UC Discovery grant
to pursue CCR1. It was not a lot of money,
but that money along with fellowships that
Samantha managed to garner, enabled us
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FIGURE 1 | (A) Undocked model of the complex between CCR2 (white
ribbon) and MCP-1 (cyan ribbon) based on mutagenesis and reproduced
directly from Hemmerich et al. (12). The model features a number of basic
residues (blue CPK) on MCP-1 that are important for binding. Acidic residues,
particularly a DYDY tyrosine sulfation motif (red CPK) are highlighted on the
N-terminus of CCR2. The model suggests how the DYDY motif might bind to
a pocket on MCP-1 that is flanked by the basic residue cluster, similar to that
shown (B). (B) Structure of a CXCR4:vMIP-II complex where the N-terminus
of CXCR4 is extended by two residues to include the sulfated tyrosine sTyr21
(13). vMIP-II is shown as a white mesh surface with basic residues colored
blue. CXCR4 is shown as a black ribbon with acidic and basic side chains that
make important interactions with vMIP-II shown as sticks with oxygens
colored red and nitrogens colored blue. The sulfate group on Tyr21 is shown
as a cluster of red and yellow spheres.
to hobble along. Samantha was ultimately
able to express decent levels of CCR1 and
to demonstrate reasonably high-affinity
chemokine binding to purified receptor,
and eventually we received a small NIH
grant. However, CCR1 turned out to be
a poor choice of receptor to pursue for
structural studies. Chemokine receptors,
like other GPCRs, are challenging, not only
because they are membrane proteins but
also because they are unstable and tend
to fluctuate between multiple active and
inactive conformations. As a consequence,
they tend to aggregate when extracted from
cell membranes unless heavily engineered
and stabilized by ligands. CCR1 was on
the wrong end of the challenge spectrum
because it had an exceptionally high level
of constitutive activity, which we discov-
ered later, clued in by its poor biophysical
behavior.
In 2005, I moved to University of Cali-
fornia San Diego, to be with Peter Domaille,
whom I married in 2004 (MCP-1 was def-
initely a chemoattractant!). Around 2008,
I reconnected with Ray Stevens who had
been at Berkeley when I started, but had
moved to The Scripps Research Institute
(TSRI). At TSRI, he had managed to
build a rather large NIH-funded center,
which later became the GPCR Network,
with the goal of determining the struc-
tures of as many GPCRs as possible. We
began working together and contributed
to the first structure of CXCR4 with a
cyclic peptide and small molecule antag-
onist, work that was spearheaded by his
postdoc Beili Wu (14). This collaboration
led to more substantial funding for my
lab and our computational collaborators
in the Abagyan group through an NIH
funding mechanism called PSI:Biology. We
were specifically paired with the GPCR
Network as a “biological partner” to focus
on determining structures of chemokine
receptor complexes. People in my labo-
ratory received training from the collec-
tive expertise of the GPCR Network team.
We were then able to establish key ele-
ments of infrastructure (equipment, insect
cell expression, biophysical assays) in our
laboratory so that we could operate fairly
independently, and we set our sights on
determining the structure of CXCR4 with
chemokine.
Compared to small molecule com-
plexes with chemokine receptors or other
GPCRs, which are challenging, complexes
of CXCR4 with chemokine turned out to
be even more difficult. The problem was
that the detergent solubilized complexes
were not sufficiently stable to survive crys-
tallization conditions. We came to this
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conclusion after spending ~2 years using a
strategy in which we made on the order
of 100 mg of chemokine every 2 weeks
to extract CXCR4 from membranes and
to keep it stable during the purification
process. This may make some people cry
if they do the math, but recall that Pepro-
tech was selling 50µg of chemokine for
~$650 USD, and we were basically pour-
ing it down the drain. Undeterred, but
realizing that just adding chemokine to
receptor was not the answer, we tried mak-
ing fusions of chemokine to receptor; this
strategy gave us sufficiently positive results
to make us waste yet another year before
giving up. Finally, I thought about the
disulfide trap approach that Brian Kobilka
had used to make a covalent complex of
the β2-adrenergic receptor with a small
molecule agonist (15); this seemed like
an ideal approach for a receptor with a
protein ligand because of the possibility
of coexpressing single cysteine mutants of
the receptor with cysteine mutants of the
ligand. Moreover, because of my back-
ground in NMR, I thought it might pro-
vide a way of getting structural informa-
tion in the form of disulfide-based dis-
tance restraints, even in the absence of
a crystal structure. However, after all of
these failures, imagine trying to convince
your lab that the disulfide trap approach
is a good idea, particularly when you do
not know where to start! Fortunately, the
lead post doc, Ling Qin accepted the chal-
lenge, although I am sure with consider-
able reluctance at first. Irina Kufareva, a
computational chemist in the Abagyan lab
was also on board and helped us iden-
tify an optimal disulfide pair through an
iterative process of predicting potential
disulfide pairs, experimentally testing coex-
pressed cysteine mutants of CXCR4 and
chemokine for the presence and abundance
of disulfide trapped complex, and evaluat-
ing the quality of the covalent complexes
by various biophysical metrics. We pur-
sued complexes of CXCR4 with both antag-
onist variants of the endogenous ligand
CXCL12 (SDF-1) and the viral antagonist
vMIP-II; antagonist ligands were chosen
because we knew that WT CXCL12, an ago-
nist, required G protein for high affinity,
which would have added yet another enor-
mous degree of complexity. Fortunately,
in the first round of experiments with 11
different pairs, we identified one disulfide
trap “hit” – just enough to be encouraging.
Irina Kufareva was then able to use that hit
as an experimental restraint in computa-
tional docking experiments to predict addi-
tional potential disulfide pairs, and even-
tually we identified a well-behaved com-
plex of CXCR4 with vMIP-II, which crys-
tallized (13) (Figure 1B). This structure
explained a lot of biochemical data, and
gave us insight into several other complexes
including CXCR4 with CXCL12; it also
provided insight into the specificity of CC
versus CXC chemokines for their respec-
tive receptors, and further illustrated the
structural plasticity of chemokine recep-
tors, which enables them to recognize very
different types of ligands. However, many
more structures including agonist com-
plexes will be required to fully under-
stand how chemokines activate (or inhibit)
their receptors, how even single amino acid
changes can lead to changes in pharmacol-
ogy (agonist versus antagonist responses),
and the full basis of receptor:ligand speci-
ficity. Moreover, ternary complexes with
intracellular signaling partners will be
needed to understand the structural basis
of the signaling and trafficking fate of
receptors after chemokines bind, and how
one can exploit this knowledge to develop
drugs with finely tuned pharmacological
properties.
The total elapsed time from the identi-
fication of the first disulfide trap to pub-
lication of the structure in January 2015
was ~2.5 years, but that was only after sev-
eral years of failed strategies. Moreover,
about 12 years elapsed between when we
embarked on trying to express chemokine
receptors for structural studies, and when
we published the structure. During this
time, I often wondered if I was out of my
mind to go down this road; it certainly was
not favorable for my publication record. I
also wondered whether I should have taken
over my grandmother’s ice cream busi-
ness, “Handel’s,” instead of pursuing sci-
ence. Hopefully, going forward, additional
structures will yield to crystallization a little
faster and with a little less sweat. Hope-
fully, the funding would not dry up before
we complete at least a structure of MCP-
1 with CCR2. And hopefully, these and
other structures will aid in the develop-
ment of drugs that target the chemokine
receptor axis. Then it will all have been
worth it.
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